Inotiv · 3 days ago
Principal Scientist - Biotransformation
St Louis, MO
Full-time
Onsite
Senior Level, Lead/Staff
2+ years expInotiv is a growing contemporary drug discovery and development company, and they are seeking a Principal Scientist of Biotransformation. The role involves identifying enzymatic pathways for drug metabolism and collaborating with various teams to establish methodologies for drug clearance predictions.
BiopharmaLife ScienceMedical DevicePharmaceutical
Hiring Manager
Julie Melton, EdD
Responsibilities
Design and execute laboratory studies aimed at identifying the enzymatic pathways that metabolize small molecule, peptide, and oligonucleotide therapeutics employing a contemporary approach methodology to establish the primary enzyme(s) contributing to the in vitro metabolism of a drug candidate(s)
Design and execute laboratory studies to elucidate primary drug clearance mechanisms in vitro, employing contemporary approach methodology to establish in vitro to in vivo correlations for anticipated drug clearance towards the prediction of human half life
Design and collaborate with in vivo pharmacology & toxicology team members to execute ADME studies (non radiolabeled); elucidating the disposition of drug candidate molecules as it pertains to absorption, distribution, metabolism, and excretion; supplementing with in vitro protein binding, and blood distribution
For oligonucleotide and peptide molecules, design and execute in vitro studies aimed at elucidating the exonuclease/endonuclease and peptidase(s) metabolism of drug candidates, respectively
Collaborate with the Toxicology Department to establish cellular models of drug metabolism, induction, and predictive toxicologic mechanisms
Qualification
Required
PhD in Organic Chemistry, Biochemistry, Analytical Chemistry or related discipline with 2-5 years direct industrial biotransformation experience following Post Doctoral training
M.Sc. in a discipline previously described with 5-7 years direct industrial biotransformation experience
Experience conducting in vitro and ex vivo biotransformation assays utilizing LC–MS/MS techniques for quantitation and structure elucidation
Experience, skills, and abilities must include knowledge of contemporary bioanalytical techniques, including wet chemistry separations, liquid chromatography, and mass spectrometric analysis, instrument operation, and data processing
Ability to incorporate software in the maintenance of databases to collate and catalog records and inventory
Independence in the laboratory and data work-up phases of research
A working knowledge and awareness of general laboratory procedures
Good written and oral communication skills
Ability to adhere to all safety regulations and procedures
Working command of in vitro kinetic analysis and utilization of contemporary mathematical models to effectively analyze, interpret and/or model drug clearance, predicted half life, and drug-drug interactions
Ability to perform mass spectrometry data collection, analysis and interpretation experience via LC-MS/MS
Preferred
Knowledge of enzyme kinetics desirable
Candidates possessing a command of Pharmacokinetic modeling, analysis, interpretation and simulation desirable
Benefits
Health and dental coverage
Short- and long-term disability
Paid time off
Paid parental leave
401K participation with company match
And more
Company
Inotiv
Inotiv provides biopharmaceutical analytical, reproductive toxicology, medical device testing, DMPK, consulting and pathological services.
1001-5000 employees
H1B Sponsorship
Inotiv has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (1)
2024 (1)
2023 (2)
2022 (1)
Funding
Current Stage
Public CompanyTotal Funding
$27.64MKey Investors
Indiana Economic Development Corporation
2024-12-18Post Ipo Equity· $27.6M
2022-06-20Grant· $0.04M
1997-11-28IPO
Leadership Team
Greg Beattie
Chief Operating Officer
Recent News
2025-12-13
Company data provided by crunchbase